ESSA Pharma Inc.

NasdaqCM EPIX

ESSA Pharma Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD -67.88 K

ESSA Pharma Inc. Gross Profit is USD -67.88 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 42.71% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

ESSA Pharma Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -118.49 K, a 2.71% change year over year.
ESSA Pharma Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -121.79 K, a -48.73% change year over year.
ESSA Pharma Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -81.88 K, a 0.00% change year over year.
ESSA Pharma Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: EPIX

ESSA Pharma Inc.

CEO	Dr. David Ross Parkinson M.D.
IPO Date	March 13, 2015
Location	Canada
Headquarters	999 West Broadway
Employees	50
Sector	Healthcare
Industries Biotechnology Clinical Trials Personal Care Pharmaceuticals

Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years